Tibet Cheezheng Tibetan Medicine Co Ltd (002287) - Net Assets
Based on the latest financial reports, Tibet Cheezheng Tibetan Medicine Co Ltd (002287) has net assets worth CN¥5.09 Billion CNY (≈ $744.59 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.66 Billion ≈ $974.13 Million USD) and total liabilities (CN¥1.57 Billion ≈ $229.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002287 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.09 Billion |
| % of Total Assets | 76.44% |
| Annual Growth Rate | 13.42% |
| 5-Year Change | 55.12% |
| 10-Year Change | 185.24% |
| Growth Volatility | 25.2 |
Tibet Cheezheng Tibetan Medicine Co Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Tibet Cheezheng Tibetan Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. See Tibet Cheezheng Tibetan Medicine Co Ltd (002287) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tibet Cheezheng Tibetan Medicine Co Ltd (2006–2025)
The table below shows the annual net assets of Tibet Cheezheng Tibetan Medicine Co Ltd from 2006 to 2025. For live valuation and market cap data, see Tibet Cheezheng Tibetan Medicine Co Ltd (002287) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.00 Billion ≈ $731.01 Million |
+21.45% |
| 2024-12-31 | CN¥4.11 Billion ≈ $601.91 Million |
+9.10% |
| 2023-12-31 | CN¥3.77 Billion ≈ $551.69 Million |
+11.29% |
| 2022-12-31 | CN¥3.39 Billion ≈ $495.72 Million |
+5.19% |
| 2021-12-31 | CN¥3.22 Billion ≈ $471.24 Million |
+22.23% |
| 2020-12-31 | CN¥2.63 Billion ≈ $385.52 Million |
+16.48% |
| 2019-12-31 | CN¥2.26 Billion ≈ $330.99 Million |
+10.59% |
| 2018-12-31 | CN¥2.05 Billion ≈ $299.28 Million |
+8.00% |
| 2017-12-31 | CN¥1.89 Billion ≈ $277.12 Million |
+8.13% |
| 2016-12-31 | CN¥1.75 Billion ≈ $256.28 Million |
+6.07% |
| 2015-12-31 | CN¥1.65 Billion ≈ $241.61 Million |
+6.54% |
| 2014-12-31 | CN¥1.55 Billion ≈ $226.77 Million |
+7.01% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.92 Million |
+7.14% |
| 2012-12-31 | CN¥1.35 Billion ≈ $197.79 Million |
+5.80% |
| 2011-12-31 | CN¥1.28 Billion ≈ $186.94 Million |
+5.64% |
| 2010-12-31 | CN¥1.21 Billion ≈ $176.96 Million |
+5.65% |
| 2009-12-31 | CN¥1.14 Billion ≈ $167.50 Million |
+115.05% |
| 2008-12-31 | CN¥532.28 Million ≈ $77.89 Million |
+34.30% |
| 2007-12-31 | CN¥396.33 Million ≈ $58.00 Million |
-13.20% |
| 2006-12-31 | CN¥456.61 Million ≈ $66.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Cheezheng Tibetan Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 727.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.52 Billion | 51.02% |
| Other Components | CN¥2.42 Billion | 48.98% |
| Total Equity | CN¥4.95 Billion | 100.00% |
Tibet Cheezheng Tibetan Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Tibet Cheezheng Tibetan Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tongyu Heavy Industry
SHE:300185
|
$1.64 Billion |
|
Pfeiffer Vacuum Technology AG
F:PFV
|
$1.64 Billion |
|
Thaifoods Group Public Company Limited
BK:TFG
|
$1.64 Billion |
|
Ventive Hospitality Ltd
NSE:VENTIVE
|
$1.64 Billion |
|
Jiangsu Tongguang Electronic Wire&Cable Co Ltd
SHE:300265
|
$1.64 Billion |
|
Archi Indonesia Tbk PT
JK:ARCI
|
$1.64 Billion |
|
Companhia Siderúrgica Nacional
MX:SIDN
|
$1.64 Billion |
|
Suning Commerce Group Co Ltd
SHE:002024
|
$1.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Cheezheng Tibetan Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,064,375,038 to 4,947,659,808, a change of 883,284,770 (21.7%).
- Net income of 646,231,100 contributed positively to equity growth.
- Dividend payments of 453,044,867 reduced retained earnings.
- Other comprehensive income decreased equity by 134,347,484.
- Other factors increased equity by 824,446,021.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥646.23 Million | +13.06% |
| Dividends Paid | CN¥453.04 Million | -9.16% |
| Other Comprehensive Income | CN¥-134.35 Million | -2.72% |
| Other Changes | CN¥824.45 Million | +16.66% |
| Total Change | CN¥- | 21.73% |
Book Value vs Market Value Analysis
This analysis compares Tibet Cheezheng Tibetan Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.26x to 2.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.97 | CN¥19.61 | x |
| 2007-12-31 | CN¥0.84 | CN¥19.61 | x |
| 2008-12-31 | CN¥1.11 | CN¥19.61 | x |
| 2009-12-31 | CN¥2.30 | CN¥19.61 | x |
| 2010-12-31 | CN¥2.25 | CN¥19.61 | x |
| 2011-12-31 | CN¥2.36 | CN¥19.61 | x |
| 2012-12-31 | CN¥2.51 | CN¥19.61 | x |
| 2013-12-31 | CN¥2.70 | CN¥19.61 | x |
| 2014-12-31 | CN¥2.88 | CN¥19.61 | x |
| 2015-12-31 | CN¥3.06 | CN¥19.61 | x |
| 2016-12-31 | CN¥3.29 | CN¥19.61 | x |
| 2017-12-31 | CN¥3.56 | CN¥19.61 | x |
| 2018-12-31 | CN¥3.82 | CN¥19.61 | x |
| 2019-12-31 | CN¥4.25 | CN¥19.61 | x |
| 2020-12-31 | CN¥4.95 | CN¥19.61 | x |
| 2021-12-31 | CN¥5.99 | CN¥19.61 | x |
| 2022-12-31 | CN¥6.29 | CN¥19.61 | x |
| 2023-12-31 | CN¥7.02 | CN¥19.61 | x |
| 2024-12-31 | CN¥7.66 | CN¥19.61 | x |
| 2025-12-31 | CN¥9.10 | CN¥19.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Cheezheng Tibetan Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.06%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.75%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.40x
- Recent ROE (13.06%) is below the historical average (17.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 23.29% | 39.55% | 0.45x | 1.30x | CN¥60.46 Million |
| 2007 | 29.31% | 34.14% | 0.66x | 1.30x | CN¥76.31 Million |
| 2008 | 25.57% | 32.84% | 0.65x | 1.19x | CN¥82.69 Million |
| 2009 | 14.07% | 34.27% | 0.36x | 1.13x | CN¥46.50 Million |
| 2010 | 14.35% | 32.55% | 0.40x | 1.11x | CN¥51.69 Million |
| 2011 | 13.72% | 21.63% | 0.58x | 1.09x | CN¥46.25 Million |
| 2012 | 14.39% | 20.36% | 0.65x | 1.08x | CN¥58.06 Million |
| 2013 | 15.15% | 22.01% | 0.63x | 1.09x | CN¥72.50 Million |
| 2014 | 15.79% | 25.00% | 0.53x | 1.19x | CN¥87.12 Million |
| 2015 | 16.44% | 26.63% | 0.48x | 1.28x | CN¥103.80 Million |
| 2016 | 16.71% | 29.93% | 0.47x | 1.20x | CN¥116.41 Million |
| 2017 | 16.03% | 28.57% | 0.46x | 1.22x | CN¥113.14 Million |
| 2018 | 15.71% | 26.27% | 0.52x | 1.14x | CN¥115.84 Million |
| 2019 | 16.22% | 25.97% | 0.47x | 1.33x | CN¥139.70 Million |
| 2020 | 15.43% | 27.20% | 0.33x | 1.70x | CN¥142.15 Million |
| 2021 | 22.59% | 40.43% | 0.32x | 1.76x | CN¥398.97 Million |
| 2022 | 14.16% | 23.11% | 0.35x | 1.76x | CN¥138.94 Million |
| 2023 | 15.62% | 28.42% | 0.32x | 1.69x | CN¥209.17 Million |
| 2024 | 14.33% | 24.91% | 0.34x | 1.67x | CN¥175.84 Million |
| 2025 | 13.06% | 26.75% | 0.35x | 1.40x | CN¥151.47 Million |
Industry Comparison
This section compares Tibet Cheezheng Tibetan Medicine Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,564,517,969
- Average return on equity (ROE) among peers: 0.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | CN¥5.09 Billion | 23.29% | 0.31x | $1.64 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
About Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral tibetan medicines, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculo… Read more